Patent · US Active

iRNA agents targeting VEGF

US8293719B2 · kind B2 · utility

5Cited by

7References

25Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Antonin de Fougerolles · Waterloo, BE
Maria Frank-Kamenetsky · Brookline, US
Muthiah Manoharan · Carlsbad, US
Kallanthottathil G. Rajeev · Wayland, US
Philipp Hadwiger · Kulmbach, DE

Key dates

Filing date	Mar 8, 2011
Grant date	Oct 23, 2012
Priority date	—
Expiry date	Mar 8, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.